Misc. information on blood issues

[Guest guest]

24 Aug 2009

A new analysis has found that adolescents and young adults who were recently

diagnosed with blood-related cancers have better long-term survival rates than

those who were diagnosed in the 1980s. Published in the November 1, 2009 issue

of Cancer, a peer-reviewed journal of the American Cancer Society, the study

indicates that significant advances have been made in the treatment of 15 to 24

year-olds with leukemias and lymphomas; however, survival rates in this age

group are still lower than those seen in younger children.

http://www.medicalnewstoday.com/articles/161615.php

*************************************

I know some of you who suffer from low platelets will be interested in

this article - dated Augus 21, 2009.

" Cerus Corporation (NASDAQ:CERS) announced that the Swiss regulatory body,

Swissmedic, has approved the use of platelet components treated with Cerus'

INTERCEPT Blood System. The approval extends permitted storage time for

platelets to seven days with INTERCEPT treatment, compared to five days without

treatment.

" The regulatory review process by Swissmedic is similar to the regulatory

processes in France (Afssaps) and Germany ( Ehrlich Institute), in which

INTERCEPT-treated blood components have been approved as a biologic for patient

use. Cerus has previously received CE mark approval for its INTERCEPT platelet

and plasma systems, which allows Cerus to sell the systems in the European

Union.

" The INTERCEPT platelet system has been piloted in Basel over the past three

years and also has been used in clinical studies elsewhere in Switzerland. It is

estimated that Switzerland produces approximately 20,000 platelet doses and

75,000 plasma units for transfusion annually. The INTERCEPT plasma system is

under review by Swissmedic. "

Source

Cerus Corp.

Cerus Corporation (NASDAQ:CERS) announced that the Swiss regulatory body,

Swissmedic, has approved the use of platelet components treated with Cerus'

INTERCEPT Blood System. The approval extends permitted storage time for

platelets to seven days with INTERCEPT treatment, compared to five days without

treatment.

The regulatory review process by Swissmedic is similar to the regulatory

processes in France (Afssaps) and Germany ( Ehrlich Institute), in which

INTERCEPT-treated blood components have been approved as a biologic for patient

use. Cerus has previously received CE mark approval for its INTERCEPT platelet

and plasma systems, which allows Cerus to sell the systems in the European

Union.

The INTERCEPT platelet system has been piloted in Basel over the past three

years and also has been used in clinical studies elsewhere in Switzerland. It is

estimated that Switzerland produces approximately 20,000 platelet doses and

75,000 plasma units for transfusion annually. The INTERCEPT plasma system is

under review by Swissmedic.

Source

Cerus

Cerus Corporation (NASDAQ:CERS) announced that the Swiss regulatory body,

Swissmedic, has approved the use of platelet components treated with Cerus'

INTERCEPT Blood System. The approval extends permitted storage time for

platelets to seven days with INTERCEPT treatment, compared to five days without

treatment.

The regulatory review process by Swissmedic is similar to the regulatory

processes in France (Afssaps) and Germany ( Ehrlich Institute), in which

INTERCEPT-treated blood components have been approved as a biologic for patient

use. Cerus has previously received CE mark approval for its INTERCEPT platelet

and plasma systems, which allows Cerus to sell the systems in the European

Union.

The INTERCEPT platelet system has been piloted in Basel over the past three

years and also has been used in clinical studies elsewhere in Switzerland. It is

estimated that Switzerland produces approximately 20,000 platelet doses and

75,000 plasma units for transfusion annually. The INTERCEPT plasma system is

under review by Swissmedic.

Source

Cerus

http://www.medicalnewstoday.com/articles/161360.php

FYI,

Lottie Duthu